Corbus Pharmaceuticals Could Achieve 3 Clinical Inflection Points Over The Next 12 Months

Catalysts In Pipeline

Corbus' lead product Resunab (JBT-101) is being studied for the treatment of rare inflammatory and fibrotic diseases. The company is conducting three Phase 2 clinical trials in patients with cystic fibrosis (CF), dermatomyositis (DM) and diffuse cutaneous systemic sclerosis.

Further, Corbus plans to initiate a fourth Phase 2 program in systemic lupus erythematosus (SLE) by the end of first half of 2017.

The company's studies show that Resunab restores the body's natural ability to reverse pro-inflammatory and pro-fibrotic drivers, hence restoring homeostasis and without psychotropic effects.

Related Link: Corbus Pharma Enrolls Last Subject In Phase 2 Study

"Corbus has also identified an ultrapure formulation of the drug with unanticipated properties, which could lead to patent extension until 2033," analyst Elemer Piros wrote in a note.

Timeline

• November 2016: Corbus plans to unveil initial efficacy results in three distinct orphan indications, beginning with diffuse cutaneous systemic sclerosis (dcSSc).
• January 2017: Cystic fibrosis (CF).
• 2H 2017: Dermatomyositis.

"The combined market potential of these indications is $3 billion, addressing 44,000 patients, by our estimates," Piros continued.

Shares of Corbus rose 2.18 percent on Tuesday to close the session at $7.02.

In Wednesday's pre-market, Corbus was up 9.69 percent at $7.70.

Full ratings data available on Benzinga Pro.